Pulmonary hypertension (PH) is a complex and progressive disease characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance. This article aims to provide a comprehensive understanding of PH, its pathophysiology, clinical presentation, diagnosis, and management strategies.
PH is primarily a disease of the small pulmonary arteries, which undergo vasoconstriction, vascular remodeling, and thrombosis in situ. These changes lead to increased pulmonary vascular resistance, right ventricular overload, and eventually right heart failure if left untreated.
Patients with PH often present with dyspnea, fatigue, chest pain, syncope, and signs of right heart failure. The diagnosis of PH is made based on a mean pulmonary artery pressure ≥25 mmHg at rest, as measured by right heart catheterization. Additional diagnostic tools include echocardiography, pulmonary function tests, and computed tomography of the chest.
The management of PH is multidimensional and includes general measures, targeted drug therapy, and in severe cases, lung transplantation. General measures include supportive care, physical activity, and supplemental oxygen. Targeted drug therapies aim to reverse the pathophysiological changes in the pulmonary arteries. These include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. Lung transplantation is reserved for patients with advanced disease who fail to respond to medical therapy.
Understanding the fundamentals of PH is crucial for prompt diagnosis and effective management. The complexity of the disease necessitates a multidisciplinary approach and a thorough understanding of its pathophysiology, clinical presentation, and management strategies. By staying abreast of the latest research and treatment modalities, healthcare professionals can provide optimal care for patients with this challenging condition.
1.
In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".
2.
Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.
3.
Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer
4.
CAR T cells improve patients' quality of life: a study
5.
Preoperative Embolization Linked to Relapse-Free Survival in Meningioma
1.
The Digital Revolution in Oncology - How Software, AI, and Data are Reshaping Cancer Care by 2025
2.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
3.
Bone Marrow Niche Remodeling in Hematologic Dysfunction
4.
Public Health Strategies for Expanding Early Support Systems in Blood Disorders
5.
Clinical Pharmacology of Megakaryocyte Maturation-Targeted Therapeutics
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation